Treating Hepatitis C Virus Reinfection With 8 Weeks of Ledipasvir/Sofosbuvir Achieves Sustained Virologic Response

Kelsey M Rife; Erin J Lea; Amy A Hirsch; Yngve Falck-Ytter

doi:10.12788/fp.0137

Treating Hepatitis C Virus Reinfection With 8 Weeks of Ledipasvir/Sofosbuvir Achieves Sustained Virologic Response

Fed Pract. 2021 Jun;38(6):282-285. doi: 10.12788/fp.0137.

Authors

Kelsey M Rife¹, Erin J Lea¹, Amy A Hirsch¹, Yngve Falck-Ytter¹

Affiliation

¹ is a Hepatology Clinical Pharmacy Specialist, is an Infectious Diseases Clinical Pharmacist, is the Chief of the Gastroenterology and Hepatology Section, and is a Behavioral Health Psychologist, all at US Department of Veterans Affairs Northeast Ohio Healthcare System in Cleveland. Yngve Falck-Ytter is a Professor of Medicine, Erin Lea is an Adjunct Assistant Professor in the Department of Psychological Sciences, and Amy Hirsch is a Senior Clinical Instructor in the College of Medicine, all at Case Western Reserve University. Yngve Falck-Ytter is Faculty for the Gastroenterology Fellowship Program at University Hospitals.

Abstract

Three patients reinfected with hepatitis C virus after a sustained virologic response were considered treatment naïve and treated with a short-course direct acting antiviral regimen.